OncoMatch

OncoMatch/Clinical Trials/NCT06549595

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

Is NCT06549595 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Surovatamig and R-CHOP for untreated follicular lymphoma.

Phase 3RecruitingAstraZenecaNCT06549595Data as of Jun 2026Location: International · 19 countries

Treatment: Surovatamig · R-CHOP · R-CVP · BRThis is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard immunochemotherapy regimen, conducted in participants with untreated FL.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

SurovatamigR-CHOPR-CVPBR

Cancer type

Non-Hodgkin Lymphoma

Disease stage

Required: Stage II, III, IV

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Demographics

Ages ≤ 130

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Lab requirements

Blood counts

adequate hematological function

Kidney function

adequate renal function

Liver function

adequate liver function

Cardiac function

adequate cardiac function

Adequate liver, hematological, renal and cardiac function.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Research Site · Anchorage, Alaska
  • Research Site · Aurora, Colorado
  • Research Site · New Haven, Connecticut
  • Research Site · Ann Arbor, Michigan
  • Research Site · New York, New York

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT06549595 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

What disease stage is eligible?

Stage II or III or IV is required.

Is there an age limit?

Yes. Patients must be 130 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify